Nicolai Haugsted
The battle of weightloss-medicine keeps escalating, as new product has entered the market.
Needles have become almost unavoidable in the booming world of weight-loss medicine. Weekly injections, strict schedules and fridge storage have turned appetite-control treatments into a routine many patients tolerate rather than enjoy.
Pharmaceutical giant Eli Lilly now wants to change that equation with a new pill designed to compete directly against blockbuster drugs like Ozempic and Mounjaro.
New tablet enters weight-loss race
Eli Lilly recently introduced Foundayo, the commercial name for orforglipron, an oral GLP-1 medication aimed at people seeking weight-loss support without injections.
Unlike Ozempic and Mounjaro, which rely on weekly injections, Foundayo is taken as a daily tablet.
Medical specialists say the drug works similarly to other GLP-1 treatments by mimicking hormones involved in appetite regulation and blood sugar control. Patients typically feel fuller for longer periods and experience reduced hunger cravings.
Researchers have long used GLP-1 medications primarily for diabetes treatment, though widespread attention around dramatic weight loss transformed the category into one of the pharmaceutical industry’s fastest-growing markets.
Doctors explain how the pill works
Healthcare experts say convenience may become Foundayo’s biggest selling point.
Dr. Donald Grant, senior clinical advisor at The Independent Pharmacy, explained that the treatment activates receptors involved in appetite, digestion and glucose regulation.
According to Grant, the medication may also slow stomach emptying while helping users maintain steadier blood sugar levels over time.
Specialists believe those combined effects can support sustainable calorie reduction and long-term weight management when paired with lifestyle changes.
Could users switch from injections?
Growing interest around tablet-based alternatives has already raised questions from people currently using injectable treatments like Ozempic or Mounjaro.
Medical professionals warn, however, that switching between treatments should not happen casually.
Doctors say both injections and oral GLP-1 medicines affect appetite similarly, but dosage timing, absorption and side effects can differ significantly from patient to patient.
Healthcare providers therefore recommend supervised transitions rather than abrupt medication changes.
Early trial results show promise
Clinical trial data released so far suggests Foundayo could become a serious competitor inside the rapidly expanding obesity-treatment market.
Phase 2 trial results showed participants losing up to 14.7 percent of their body weight over 36 weeks when combined with healthy lifestyle adjustments.
By comparison, Mounjaro users have reportedly achieved weight reductions above 20 percent in some clinical studies, while Ozempic patients generally average between 10 and 15 percent depending on dosage and treatment duration.
Despite slightly lower headline numbers compared with injectable rivals, analysts believe the simplicity of a pill could dramatically broaden interest among patients reluctant to use needles.
